Skip to main content

Call for papers - Clinical trials resource

Guest Editor

Christophe Le Tourneau, MD, PhD, Institut Curie, France

Submission Status: Open   |   Submission Deadline: 6 June 2025

Genome Medicine is pleased to announce a call for papers for our Clinical trials resource, guest edited by Christophe Le Tourneau from the Institut Curie. We encourage work from academic-industry partnerships as well as collaboration among scientists from multi-disciplinary fields.


New Content ItemThis Collection supports and amplifies research related to SDG 3: Good Health & Well-Being.

About the Collection

Genome Medicine is pleased to announce a call for papers for our Clinical trials resource, guest edited by Christophe Le Tourneau from the Institut Curie. We encourage work from academic-industry partnerships as well as collaboration among scientists from multi-disciplinary fields.

We are now inviting the submission of Research, Method, and Guideline manuscripts of outstanding interest covering original reports on human clinical trials including but not limited to the following topics:

  • Screening, detection, and diagnostics
  • Diverse populations
  • Novel treatment strategies
  • Molecular profiling
  • Longitudinal disease monitoring 
  • Infectious disease treatments and dynamics
  • Cancer therapeutics 
  • Vaccine development
  • Epidemiological studies
  • Gene-editing therapeutics
  • Public health genomics and surveillance


To submit your manuscript, please use the Genome Medicine online submission system and indicate in your covering letter that you would like the article to be considered for the Clinical Trials Resource. If you would like to inquire about the suitability of a manuscript for consideration, please email editorial@genomemedicine.com.

This collection of articles has not been sponsored and articles will undergo the journal’s standard peer-review process. The Guest Editor declares that they have no competing interests. The Guest Editor serves an advisory role to guide the scope of the collection and commissioned content; final editorial decisions lie with the Editor.

Please note that we will be unable to consider retrospectively registered trials per the journal’s policy.
 

Image credit: © WS Studio 1985 / stock.adobe.com

Meet the Guest Editor

Back to top

Christophe Le Tourneau, MD, PhD, Institut Curie, France

Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at Paris-Saclay University. He heads the Department of Drug Development and Innovation (D3i), as well as the Head and Neck Cancer Clinic. Christophe is leading the early phase clinical trials program of the Institut Curie. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology. He ran the first randomized precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advanced cancer. Christophe Le Tourneau leads the UNICANCER Precision Medicine group. He is the vice-chair of the GORTEC Head and Neck cancer group. Christophe has participated in the Developmental Therapeutics track of the ASCO from 2017 to 2019 and has been the track leader in 2018. He has been a member of the Developmental Therapeutics and the Head and Neck Cancer tracks of ESMO on several occasions. He has published 270+ peer-reviewed papers in international journals.
 

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Method, and Guideline manuscripts of outstanding interest covering original reports on human clinical trials. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Clinical trials resource" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.